Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
03 août 2017 08h23 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced the pricing of its underwritten public...
Agile Therapeutics Announces Proposed Offering of Common Stock
02 août 2017 16h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
28 juil. 2017 07h30 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
27 juil. 2017 16h11 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...